FNDC3B and acute myeloid leukemia: Proteomic analysis identified 447 differentially expressed proteins between pre- and post-treatment samples, among which FNDC3B, a key protein in the prognostic signature, was significantly downregulated after VD-CAG intervention.<h4>Conclusions</h4>This study reveals the molecular alterations associated with VD-CAG treatment in non-M3 AML, and provides a validated 11-gene prognostic signature.